pidemiological studies have established a strong correlation between cigarette smoking and the development and progression of atherosclerosis, myocardial infarction, vascular graft failure, and death from coronary artery disease. [1] [2] [3] Because cigarette smoke is a complex mixture of more than 4000 chemical constituents that are distributed in particulate and gaseous phases, it has been difficult to identify the components in cigarette smoke of pathophysiological relevance. 3 Recently, it has been documented that nicotine, a major component of cigarette smoke, stimulates proliferation of both vascular smooth muscle cells (VSMC) and endothelial cells (EC), and promotes the secretion of basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), prostacyclin, and endothelin from VSMC and EC. 4 -8 In addition, nicotine induced the expression of several gene-encoding molecules that have been shown to be involved in atherogenesis, such as endothelial nitric-oxide synthase, plasminogen activator inhibitor-1, and angiotensin converting enzyme. 9 A very recent study has clearly demonstrated that nicotine promotes the growth of atherosclerotic plaque and tumors, partly because of stimulating pathological angiogenesis. 10 These results suggest that nicotine is involved in the pathogenesis of tobacco-related cardiovascular diseases. However, the underlying intracellular signal mechanism has been less explored.
Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system, plays an important role in the regulation of cardiovascular homeostasis. Exaggerated Ang II action via the Ang II type 1 (AT 1 ) receptor has been strongly implicated in the pathogenesis of hypertension, heart failure, hypertrophy, arteriosclerosis, and renal diseases characterized by abnormal proliferation of VSMC and fibroblasts and the accumulation of an extracellular matrix. 11 Moreover, the pathophysiological actions of Ang II are modulated by other growth factors, such as insulin and insulin-like growth factors, leading to an enhanced AT 1 receptor-mediated functional response, such as proliferation of VSMC. 12, 13 Accordingly, the notion that interaction of nicotine and Ang II may play a role in the pathophysiology of smoking-related cardiovascular diseases appears to be an intriguing issue. In the present study, we investigated the possibility that nicotine enhances Ang II-induced vasotrophic effects and examined the cellular and molecular mechanisms of potential cross-talk of nicotine and Ang II in arterial VSMC and fibroblasts.
Methods

Cell Culture and Measurement of DNA Synthesis by [ 3 H]Thymidine Incorporation
Adult rat aortic VSMC and adventitial fibroblasts were prepared from adult Sprague-Dawley rat thoracic aortae (Clea Japan Inc, Tokyo, Japan) as previously described. 14, 15 Cells at passage 3 to 8 were used for the following experiments. Cells were serum-starved for 48 hours to induce a quiescent state. Subconfluent and quiescent cells cultured in 24-well plates (Techno Plastic Products AG, Trasadingen, Switzerland) were stimulated with various stimuli for 12 hours and pulsed with 1 Ci/mL [ 3 H]-thymidine specific activity (Du Pont NEN Research Products) for an additional 24 hours. The cells were washed twice with ice-cold phosphate-buffered saline (PBS) and subsequently incubated with ice-cold 5% trichloroacetic acid for 20 minutes at 4°C. The cells were washed twice with ice-cold 5% trichloroacetic acid, then with ice-cold PBS, and lysed with 0.5% N NaOH. The radioactivity of the cell lysate was determined using a liquid scintillation counter. AT 1 or AT 2 receptor binding was measured as previously described. 14 
Transfection and c-fos Promoter Assay
VSMC were seeded in 6-well plates and transfected with c-fosluciferase reporter gene (p2FTL, 1 g) using LipofectAMINE PLUS reagent (GIBCO-BRL) according to the manufacturer's instructions. The fos-luciferase reporter gene p2FTL consists of two copies of the c-fos 5Ј-regulated enhancer element (-357 to -276), the herpes simplex virus thymidine kinase gene promoter (-200 to ϩ70), and the luciferase gene. 16 At 48 hours after transfection, the transfected cells were incubated with a serum-free medium for 24 hours. Then the cells were treated with Ang II (10 -7 mol/L) and/or nicotine (10 -8 mol/L) for 4 hours, washed with PBS, and lysed with a 200-L cell lysis buffer (Promega Corp) at room temperature. Then, 10 L of the cell extract was mixed with a 100-L luciferase assay reagent (Promega Corp), and luciferase activity was measured.
Western Blot Analysis
Total proteins were prepared from the cultured VSMC and adventitial fibroblasts, and Western blot was performed as previously described. 14 Immunoblotting was done using anti-extracellular signal-regulated kinase (ERK), anti-phospho-ERK, anti-signal transducers and activators of transcription (STAT)1, anti-phospho-STAT 1 and 3, anti-phospho-p38 MAKP, anti-p38 MAKP (New England Biolabs), and anti-STAT3 (Santa Cruz Biotechnology).
Statistical Analysis
Values are expressed as meanϮSEM in the text and figures. The data were analyzed using ANOVA. If a statistically significant effect was found, post-hoc analysis was performed to detect the difference between the groups. Values of PϽ0.05 were considered to be statistically significant.
Results
Dose-Dependent Effects of Nicotine on DNA Synthesis of VSMC and Adventitial Fibroblasts
To determine the effect of nicotine on growth of vascular cells, we first investigated the effect of nicotine on [ 3 H]thymidine incorporation as a marker of DNA synthesis using cultured VSMC and adventitial fibroblasts. We observed that nicotine at 10 -7 -10 -11 mol/L induced a 20% to 40% increase in [ 3 H]thymidine incorporation in both VSMC and adventitial fibroblasts; however, it inhibited DNA synthesis at 10 -5 mol/L ( Figure IA , available online at http://atvb.ahajournals.org). Therefore, the pattern of DNA synthesis in response to nicotine was bimodal, with stimulation at low nicotine concentrations (Ͻ10 -6 mol/L) and inhibition at high nicotine concentrations (Ͼ10 -5 mol/L). We observed that addition of nicotine (10 -8 mol/L) increased the cell number of both VSMC and fibroblasts ( Figure IB) (Figure 1 ). Next, we examined the effect of Ang II and/or nicotine on c-fos promoter activity using p2FTL-transfected cells. We observed that treatment with nicotine (10 -8 mol/L) increased c-fos transcription in both cell types, and moreover that the Ang II-induced increase in c-fos promoter activity was enhanced by nicotine treatment ( Figure  2 ). Furthermore, we examined the possibility of whether Ang II and nicotine could synergistically activate the cell growth and observed that co-administration of lower doses of nicotine (10 -12 mol/L) and Ang II (10 -10 mol/L) increased [ 3 H]thymidine incorporation (Figure 1 ) and c-fos promoter activity (Figure 2 ) both in VSMC and fibroblasts, whereas Ang II or nicotine at these doses did not affect cell growth.
Cellular Mechanism of Interaction of Nicotine and Ang II in Vascular Cell Proliferation
To examine the signaling mechanism of the enhancement of AT 1 receptor-mediated proliferation of VSMC and adventitial
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fibroblasts by nicotine, we focused on ERK activity, because the ERK pathway, which is activated by the AT 1 receptor and various growth factors, is critical for cell proliferation, differentiation, and hypertrophy. 17 We also examined whether nicotine increased AT 1 receptor-mediated activation of STAT, because STAT seems to be involved in AT 1 receptor-mediated c-fos expression in VSMC. 18 Nicotine (10 -8 mol/L) stimulation rapidly increased ERK activity, reaching a peak at 2 minutes, and declining to near basal level at 30 minutes in both cell types ( Figure II , available online at atv.ahajournals.org). Nicotine-induced ERK activation was clearly observed at 10 -7 mol/L and became more prominent at approximately 10 -9 mol/L, whereas ERK activation was hardly observed at 10 -5 mol/L nicotine ( Figure II ). In addition, nicotine stimulation induced tyrosine-and serine-phosphorylation of STAT1 and STAT3, with a similar pattern to ERK activation ( Figure II) . Ang II (10 -7 mol/L) stimulated phosphorylation of ERK and STAT in both cell types, and this AT 1 receptor-mediated activation of ERK and STAT was enhanced by nicotine treatment (data not shown). We observed that nicotine activated p38 MAPK time-and dosedependently both in VSMC and fibroblasts ( Figure II) . Furthermore, we observed that co-administration of lower doses of nicotine (10 -12 mol/L) and Ang II (10 -10 mol/L) activate the ERK, STAT, and p38MAPK both in VSMC and fibroblasts ( Figure 3) . Total protein levels of ERK, STAT, and p38MAPK were not changed in all these experimental conditions. Moreover, we observed that nicotine 
Discussion
Increasing evidence has indicated that nicotine plays a potential role in the pathogenesis of tobacco-related cardiovascular diseases; however, there is little information on the intracellular signal pathways of nicotine-mediated actions in vascular cells. To elucidate the cellular and molecular mechanisms involved in nicotine-induced effects on the vasculature, we investigated the impact of nicotine on proliferation of cultured arterial VSMC and adventitial fibroblasts. This study provided the possibility that activation of ERK, STAT, and p38MAPK is involved in the nicotine-mediated proliferation of vascular VSMC and fibroblasts. Moreover, we demonstrated that nicotine enhanced the mitogenic effects of Ang II on both cell types at least partially via increases in activity of ERK, STAT, and p38MAPK. These results suggest that the interaction of nicotine and Ang II may contribute to the pathogenesis of smoking-related cardiovascular diseases.
Exposure of VSMC and adventitial fibroblasts to nicotine at a concentration of 10 -7 -10 -9 mol/L, which is similar to the plasma concentration in cigarette smokers, 19, 20 increased DNA synthesis by 20% to 40% with increased c-fos promoter activity, as previously reported. 21 The apparently nicotinemediated mitogenic effects in vitro and the more prominent actions of nicotine in vivo (eg, promoting tumor growth and enhancing atherosclerotic lesions) 10 led us to hypothesize that nicotine may interact with other systems, thereby contributing to the development of smoking-related cardiovascular diseases. Indeed, we demonstrated that nicotine enhanced Ang II-induced DNA synthesis as well as c-fos promoter activity, with co-administration of nicotine and Ang II at lower doses, which did not affect cell growth. Because nicotine-induced DNA synthesis was not affected by either an AT 1 receptor blocker, valsartan, or an AT 2 receptor antagonist, PD123319, it is possible that nicotine potentiates Ang II-induced activation of growth-promoting signaling molecules such as ERK and STAT, 17, 18 leading to the enhancement of Ang II-induced proliferation, without influencing the transactivation of AT 1 and AT 2 receptors. Consistent with this notion, we observed that pretreatment of VSMC and adventitial fibroblasts for 48 hours with nicotine (10 -8 and 10 -7 mol/L) did not affect AT 1 and AT 2 receptor expression, suggesting that the nicotinemediated proliferation of VSMC and adventitial fibroblasts is independent of AT 1 receptor expression.
Our data showed that nicotine stimulated phosphorylation of ERK in VSMC and adventitial fibroblasts. Moreover, we observed that nicotine enhanced Ang II-induced ERK activation in both cell types. The nicotine-and/or Ang II-mediated DNA synthesis was strongly attenuated by inhibition of ERK activation with an MEK inhibitor. These results suggest that ERK is involved in nicotine-mediated vascular cell growth. Expression of the c-fos gene is regulated by the net interaction of different transcriptional factors. Activation of ERK may also result in increased production of serum response factor, and this may act in concert with the activation of STAT, a component of the nuclear sis-inducing factorcomplex, thereby resulting in an increase of c-fos transcription. 22 STAT is now known to be activated by many different extracellular signaling proteins, including cytokines, growth factors such as epidermal growth factor (EGF), PDGF, and Ang II via the AT 1 receptor. [23] [24] [25] [26] [27] Recent evidence has revealed that serine-phosphorylation as well as tyrosine-phosphorylation is required for maximal activation of STAT, and that activation of ERK has been reported to be involved in the serine-phosphorylation of STATs. 22,28 -30 We demonstrated that in response to AT 1 receptor stimulation, tyrosine-and serine-phosphorylated STAT1 and STAT3 accumulated in the nuclei of VSMC and became a component of the nuclear sis-inducing factor-complex, resulting in enhancement of c-fos promoter activity. 18 In this study, we demonstrated that nicotine increased tyrosine-and serine-phosphorylation of STAT1 and STAT3, thereby increasing c-fos promoter activity in cultured VSMC and adventitial fibroblasts. In addition, we observed that nicotine also enhanced Ang II-induced tyrosine-and serine-phosphorylation of STAT1 and STAT3, as well as increasing c-fos promoter activity. These results suggest that nicotine-mediated activation of STAT may contribute to its enhancing actions on Ang II-induced growthpromoting effects on the vasculature, although the role of nicotine-mediated STAT activation in cell growth has to be clarified in more detail in future experiments. Moreover, we demonstrated that p38MAPK is involved in Ang II-and nicotine-mediated VSMC and vascular adventitial fibroblast proliferation. Ushio-Fukai et al 31 reported that p38MAPK is a critical component of the oxidant stress-sensitive signaling pathways activated by Ang II in VSMC and indicate that it plays a crucial role in vascular hypertrophy.
Taken together, our results demonstrated that nicotine directly increased AT 1 receptor-mediated signaling and proliferation of VSMC and adventitial fibroblasts without affecting Ang II receptor expression. The role of Ang II in nicotine-mediated actions in vivo remains to be further investigated, and could provide new insights into the pathogenesis of smoking-related cardiovascular disease.
